CG Oncology Stock (NASDAQ:CGON)

Forecast Revenue Ownership Financials Chart

Previous Close

$26.10

52W Range

$14.80 - $40.47

50D Avg

$26.21

200D Avg

$28.46

Market Cap

$1.97B

Avg Vol (3M)

$1.09M

Beta

0.87

Div Yield

-

CGON Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

113

IPO Date

-

Website

CGON Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Mar 25
Operating Segments	$52.00K

Fiscal year ends in Dec 24 | Currency in USD

CGON Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$204.00K	$191.00K
Operating Income	$-114.67M	$-55.45M	$-35.25M
Net Income	$-88.04M	$-48.61M	$-35.44M
EBITDA	$-114.67M	$-55.43M	$-35.23M
Basic EPS	$-1.41	$-15.65	$-0.53
Diluted EPS	$-1.41	$-15.65	$-0.53

Fiscal year ends in Dec 24 | Currency in USD